Selected article for: "abnormal innate and acute respiratory"
Author: Giudice, Valentina; Pagliano, Pasquale; Vatrella, Alessandro; Masullo, Alfonso; Poto, Sergio; Polverino, Benedetto Maria; Gammaldi, Renato; Maglio, Angelantonio; Sellitto, Carmine; Vitale, Carolina; Serio, Bianca; Cuffa, Bianca; Borrelli, Anna; Vecchione, Carmine; Filippelli, Amelia; Selleri, Carmine
Title: Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study
  • Cord-id: bgnpqi3y
  • Document date: 2020_6_5
    • ID: bgnpqi3y
    Snippet: To date, there are no specific therapeutic strategies for treatment of COVID-19. Based on the hypothesis that complement and coagulation cascades are activated by viral infection, and might trigger an acute respiratory distress syndrome (ARDS), we report clinical outcomes of 17 consecutive cases of SARS-CoV-2-related ARDS treated (N = 7) with the novel combination of ruxolitinib, a JAK1/2 inhibitor, 10 mg/twice daily for 14 days and eculizumab, an anti-C5a complement monoclonal antibody, 900 mg
    Document: To date, there are no specific therapeutic strategies for treatment of COVID-19. Based on the hypothesis that complement and coagulation cascades are activated by viral infection, and might trigger an acute respiratory distress syndrome (ARDS), we report clinical outcomes of 17 consecutive cases of SARS-CoV-2-related ARDS treated (N = 7) with the novel combination of ruxolitinib, a JAK1/2 inhibitor, 10 mg/twice daily for 14 days and eculizumab, an anti-C5a complement monoclonal antibody, 900 mg IV/weekly for a maximum of three weeks, or with the best available therapy (N = 10). Patients treated with the combination showed significant improvements in respiratory symptoms and radiographic pulmonary lesions and decrease in circulating D-dimer levels compared to the best available therapy group. Our results support the use of combined ruxolitinib and eculizumab for treatment of severe SARS-CoV-2-related ARDS by simultaneously turning off abnormal innate and adaptive immune responses.

    Search related documents:
    Co phrase search for related documents
    • active infection and acute ards respiratory distress syndrome: 1, 2, 3, 4
    • active infection and adaptive immune response: 1, 2, 3, 4, 5
    • active infection and long period: 1
    • active infection and lopinavir ritonavir: 1, 2
    • active infection and lung inflammation: 1, 2, 3, 4, 5
    • acute ards respiratory distress syndrome and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute ards respiratory distress syndrome and additional evidence: 1, 2, 3
    • acute ards respiratory distress syndrome and long period: 1, 2
    • acute ards respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and low flow oxygen: 1
    • acute ards respiratory distress syndrome and lung inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and macrophage neutrophil: 1, 2, 3, 4, 5, 6
    • adaptive immune response and additional evidence: 1
    • adaptive immune response and lopinavir ritonavir: 1
    • adaptive immune response and lung inflammation: 1, 2, 3, 4
    • additional evidence and long period: 1
    • lopinavir ritonavir and lung inflammation: 1, 2, 3, 4, 5, 6, 7, 8
    • lung inflammation and macrophage neutrophil: 1, 2